Effectiveness of oral prednisone tapering following intravenous methylprednisolone for acute optic neuritis in multiple sclerosis
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0288366 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Adi Wilf-Yarkoni und 16 weiteren Autor:innen. Beteiligte Einrichtung: Neuroimmunology Unit, Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Multiple Sclerosis, Optic Neuritis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute optic neuritis treatment lacks standardized protocols. The value of oral prednisone taper (OPT) following intravenous methylprednisolone (IVMP) on visual outcome parameters in optic neuritis (ON) has never been explored. In the present retrospective study, we investigated whether OPT after IVMP affects the structural and functional visual outcomes of inaugural clinically isolated syndrome (CIS)- or multiple sclerosis (MS)-ON. Adult patients with acute, inaugural, unilateral CIS- or MS-ON, treated with IVMP in Germany and Israel were stratified into patients treated with IVMP alone—versus IVMP and OPT. Inclusion criteria were age ≥18, CIS or MS diagnosis according to McDonald criteria 2017, available visual acuity (VA) at nadir before treatment initiation and at follow-up ≥5 months, as well as a spectral domain optic coherence tomography (OCT) data scan at follow-up. Exclusion criteria included recurrent ON, concomitant ophthalmological comorbidities, optical coherence tomography (OCT) of insufficient quality and ON-related escalation therapy after IVMP. The structural outcome was defined as the average retinal nerve fiber layer (RNFL) difference between the ON-affected and the unaffected eye, while the functional outcome was defined as the final high-contrast best-corrected VA (HC-BCVA) at follow-up compared to nadir. The comparative analysis was performed using linear regression analysis, adjusted for sex, age, and days-to-treatment. Fifty-one patients met the inclusion criteria (25% male). The mean age was 33.9 (±10.23) years. Twenty-six patients (51%) received OPT following IVMP. There was no difference in nadir HC-BCVA between the groups (0.39 No OPT; 0.49 With OPT, P = 0.36). Adjusted linear regression analysis did not indicate an influence of OPT on RNFL thickness or on HC-BCVA (beta coefficient for RNFL difference in percentages: 0.51, 95%-CI: [-4.58, 5.59], beta coefficient for logMAR: 0.11, 95%; CI [-0.12, 0.35] at follow-up. In conclusion, the addition of OPT to IVMP did not affect RNFL thickness or the final VA in a retrospective cohort of 51 patients with inaugural acute CIS- or MS-ON. The results of this exploratory study are currently being re-examined in a large-scale, demographically diverse, prospective study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neuroimmunology Unit, Department of Neurology, Rabin Medical Center, Petah Tikva, Israel.
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Experimental and Clinical Research Center, a Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin, Berlin, Germany.
- Charité -Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Berlin, Germany.
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
- Neuroscience Clinical Research Center, Charité -Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
ORCID-Profile: Adi Wilf-Yarkoni, Kerstin Rubarth, Itay Lotan, Omer Bialer, Susanna Asseyer, Hadas Stiebel-Kalish
Zitieren
APA
Wilf-Yarkoni, A., Feldmann, K., Rubarth, K., Dorsch, E. M., Rust, R., Urman, I., Hellmann, M. A., Friedman, Y., Lotan, I., Bialer, O., Buenrostro, G. S., Zimmermann, H. G., Leutloff, C., Schmitz-Hübsch, T., Paul, F., Asseyer, S., & Stiebel-Kalish, H. (2023). Effectiveness of oral prednisone tapering following intravenous methylprednisolone for acute optic neuritis in multiple sclerosis. PLOS ONE. https://doi.org/10.1371/journal.pone.0288366
Vancouver
Wilf-Yarkoni A, Feldmann K, Rubarth K, Dorsch EM, Rust R, Urman I, et al. Effectiveness of oral prednisone tapering following intravenous methylprednisolone for acute optic neuritis in multiple sclerosis. PLOS ONE. 2023. doi:10.1371/journal.pone.0288366
BibTeX
@article{WilfYarkoni2023,
author = {Wilf-Yarkoni, Adi and Feldmann, Kristina and Rubarth, Kerstin and Dorsch, Eva-Maria and Rust, Rebekka and Urman, Ilia and Hellmann, Mark A and Friedman, Yitzhak and Lotan, Itay and Bialer, Omer and Buenrostro, Gilberto Solorza and Zimmermann, Hanna G and Leutloff, Carla and Schmitz-Hübsch, Tanja and Paul, Friedemann and Asseyer, Susanna and Stiebel-Kalish, Hadas},
title = {Effectiveness of oral prednisone tapering following intravenous methylprednisolone for acute optic neuritis in multiple sclerosis},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0288366}
}
EUVIMED